Der er ikke beskrevet dannelse af neutraliserende antistoffer efter behandling med Soliris, og der er ikke iagttaget sammenhæng mellem antistofdannelse og klinisk respons eller bivirkninger.
No patients have been reported to develop neutralizing antibodies following therapy with Soliris, and there has been no observed correlation of antibody development to clinical response or adverse events.